theranes

1701 Page Mill Road Palo Alto, CA 94304 P 650.838.9292 F 650.838.9165 theranos.com

California Department of Public Health Laboratory Field Services 850 Marina Bay Parkway, Bldg. P, 1st FL Richmond, CA 94804-6403

Via U.S. Registered Mail

Re: Theranos, Inc. (CLF 00341367)

December 17, 2014

Dear Sir or Madam:

This letter is sent to you as notification pursuant to Section 1265(g) of the California Business Professions Code of my resignation, effective as of the date of this letter, as Laboratory Director of the above-reference clinical laboratory located at 7333 Gateway Boulevard, Newark, California 94560.

Regards,

Adam Rosendorff, M.D.



State of California—Health and Human Services Agency

California Department of Public Health Laboratory Field Services



NOTIFICATION OF LABORATORY CHANGE

State License/Registration #: (CLF, CLA, CLM, CLR, C	LP, COS) CLF 00341367
CLIA ID #: 05D 05D2025714	
aboratory Name: Theranos, Inc.	10
aboratory Address: 7333 Gateway Blvd	
City, State and Zip Code: Newark, CA 94560	
Telephone Number: (650) 838-9292	
ax Number: (650) 838-9165	
E-mail Address: labsupport@the	eranos.com
Please mail completed form to: California Department of Public Health, Laboratory Field Services, ATT: Facilities Licensing, 850 Marina Bay Parkway, Bldg P, 1 st Floor, Richmond, California 94804-6403. THIS IS TO REQUEST CERTIFICATE CHANGE: THIS IS TO INFORM YOU OF A	
THIS IS TO REGUEST CERTIFICATE CHANGE.	THIS IS TO INFORM YOU OF A
From:	Change of ownership (See note below)
TO:	✓ Change of Director/Add Director (See note)
Certificate of Compliance	Note: Items above may require additional forms. See website www.cdph.ca.gov/lfs
Certificate of Accreditation	for additional information
Note: Proof of accreditation is required.	Change of site address
Provider Performed Microscopy Procedures (PPMP)	Change of laboratory name
Waiver	Change of mailing Address
Cease Testing, specialty, subspecialty and/or test	Change of telephone and/or fax
Closure of the Laboratory	From:
EFFECTIVE DATE OF CHANGE(S): 12/17/2014	
2.1 231112 31 31 M (132(0))	To/New: Resignation of Adam
	Rosendorff as Co-Director
ATTENTION, DEAD THE FOLLOW	
ATTENTION: READ THE FOLLOWING CAREFULLY BEFORE SIGNING Pursuant of 42 U.S.C. 263 a (i)(I)(B) and 42 C.F.R. 493.1840(a)(2) your laboratory's CLIA certificate may be revoked if the laboratory performs any tests not within the category of laboratory examinations authorized by your CLIA certificate. Please be advised that any person who intentionally violates the mandates of CLIA shall be subject to imprisonment, or fines, or both. See 42 U.S.C. 263a(l).	
If in the future you wish to reapply for a Certificate for moderate or high complexity testing, you must notify Laboratory Field Services and submit to an inspection <u>before</u> such testing may begin. This inspection must find the laboratory in compliance with all CLIA condition-level requirements found at 42 C.F.R. Part 493 before the laboratory may resume moderate or high complexity testing.	
For changes in certificate type, your laboratory must pay the appropriate certificate fee and/or compliance fee before the change can be effective. NOTE: This notification of change form is acceptable only if signed by the director of the laboratory. A dam Rosendor H	
Name of Director Only (print)	
A mus	12/17/2014
Signature of Director	Date

California Department of Public Health, Laboratory Field Services, 850 Marina Bay Parkway, Bldg. P, 1st FL, Richmond, CA 94804-6403 (510) 620 – 3800

DEC 2 6 2014

Adam Rosendorff, MD

Rona Aquino
California Department of Public Health
Laboratory Field Services
850 Marina Bay Parkway
Building P
Richmond
CA 94804

12/19/2014

Dear Rona

This letter is to inform you that December 17th, 2014 was my last day of employment at Theranos, Inc (CLF 341367, 05D2025714), operating at 7333 Gateway Blvd Newark CA, 94560.

Accordingly, I wish to be removed immediately as the Laboratory Director of record for Theranos.

Furthermore, I wish to make it clear that I do not sign off, endorse, or medically support, any laboratory results reported from Theranos after December 17th, 2014.

Sincerely,

Adam Rosendorff, MD

Adam Rosendorff, MD